Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

Identification of Urine PLK2 as a Marker of Bladder Tumors by Proteomic Analysis - Abstract Show Comments PDF Print E-mail
  
Thursday, 02 July 2009

Department of Urology, St. Joseph Hospital, Huwei, Yunlin, Taiwan.

This email address is being protected from spam bots, you need Javascript enabled to view it

To determine the patterns of urinary proteins in bladder cancer subjects using pooled urine from 27 bladder cancer patients.

The urine matrix was removed by acetonitrile precipitation followed by molecular weight cutoff. High performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) was used to analyze the urinary proteome. The candidate protein was validated by western blot.

A total of 146 urinary proteins were identified. The protein list was screened using bioinformatic tools, and 11 cancer-related urinary proteins were found to be potential tumor markers for bladder cancer. However, only PLK2 was identified with high confidence. This candidate protein was validated by western blot using urine samples from 14 normal subjects and 10 bladder cancer patients. Statistically significant correlations were detected between PLK2 expression and bladder transitional cell carcinoma (TCC) (P < 0.05). Urinary PLK2 had a sensitivity of 80% at a specificity of 64% for bladder TCC in the samples tested.

Our results demonstrate overexpression of PLK2 in bladder carcinomas, suggesting a possible role of PLK2 in the pathogenesis of bladder carcinomas. However, the small cohort, preliminary results, and lack of subgroup analysis (such as carcinoma in situ, high grade, and stage) in this study prevent us from drawing definitive conclusions about the diagnostic value of PLK2 in these patients. Further studies directed toward a multitude of possible carcinogenic mechanisms of PLK2 in bladder cancer are warranted.

Written by:
Tan LB, Chen KT, Yuan YC, Liao PC, Guo HR. Are you the author?

Reference:
World J Urol. 2009 Jun 9. Epub ahead of print.
doi:10.1007/s00345-009-0432-y

PubMed Abstract
PMID:19506885

UroToday.com Bladder Cancer Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

Bladder Cancer
Sponsored By